Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.
VSEE HEALTH, INC. director Kevin Lowdermilk acquired 40,107 shares of common stock at a price of
WICKERSHAM DAVID L. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director David L. Wickersham reported an equity award of 40,107 shares of common stock on
After this grant, Wickersham directly holds 1,187,671 shares of VSEE common stock.
VSEE HEALTH, INC. director Fairfax Cydonii V. acquired 40,107 shares of common stock as a stock grant under the company’s 2024 Incentive Plan, issued for services as a non-employee director for the quarter ended December 31, 2025. The grant was based on the common stock’s $0.374 closing price on December 31, 2025 and increased the director’s directly held stake to 108,504 shares of common stock.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale under a prospectus supplement, including shares issuable upon conversion or exercise of preferred stock, warrants and pre-funded warrants.
The supplement ties to private placements that closed on December 1, 2025 and December 9, 2025, and updates the prospectus with proxy and Form 8-K disclosures. The company sought and obtained stockholder approval under Nasdaq Listing Rule 5635(d) for issuance of warrants exercisable for up to 19,672,130 shares. Shares outstanding were reported as 43,244,355 as of February 2, 2026.
VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.
Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSee Health, Inc. Schedule 13G/A discloses that the reporting persons beneficially own 833,331 shares, representing 2.0% of the class. The reported position consists of Public Warrants to purchase 702,896 shares plus 130,435 shares issuable under a Warrant Exchange Agreement. The percentage calculation references 40,230,845 shares outstanding as of
VSee Health, Inc. entered a managed services agreement with GoMyRx, Inc. under which VSee will provide platform administration, customer support, vendor coordination, and reporting services. VSee will bill GoMyRx monthly for actual expenses plus a 10% markup, and the agreement runs through December 26, 2027, with optional month-to-month extensions for six months.
Separately, VSee agreed to purchase $2.0 million of GoMyRx common stock from Go Biz Holdings, LLC in a private transaction, representing a 10% ownership stake in GoMyRx. The shares are restricted securities issued under Section 4(a)(2) and Rule 506 of Regulation D.